Liver Resection for Hepatocellular Carcinoma and the Barcelona Clinic Liver Cancer Criteria: Is It Time to Push the Limits?

Naar, Leon; Hatzaras, Ioannis

doi:10.1245/s10434-020-08459-w

Cited by 2 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients with BCLC stage B, TACE was recommended as the first-line treatment. HCC patients with BCLC stage B who received TACE treatment had shorter mOS (16 to 42 months) than patients undergoing surgery (23 to 70 months) (6,(14)(15)(16)(17)(18). However, HCC patients with TACE have high recurrence due to incomplete embolization (19,20).…”

Section: Discussionmentioning

confidence: 99%

The trends and efficacy of operation in the treatment of hepatocellular carcinoma

Wu¹,

Chen²

2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Recently, the possibility was advanced that operation (including surgery, transplantation, and ablation, etc.) could be applied in hepatocellular carcinoma (HCC) patients more widely. The trend and efficacy of operation and surgery for the treatment of HCC with time was analyzed.Methods: Data from Surveillance, Epidemiology, and End Results Program (SEER) registries were used to analyze the trends in the use operation and surgery for HCC and the survival benefits of these procedures.The study included patients between the ages of 35 and 84 years diagnosed as HCC between 2004 and 2015 (n=64,019). Propensity score matching (PSM) analysis was used to reduce selection bias.Results: From 2004 to 2015, the rate of operation for HCC decreased in the localized group (P<0.001), the regional and distant group (P<0.001). Surgery rate in the localized, regional, and distant group also declined (P=0.016, P=0.009, and P=0.018, respectively). Non-operation rate increased in the localized, regional, and distant group (all P<0.001). The median overall survival (mOS) of patients in the localized, regional group who underwent surgery was longer than that of patients with non-surgical procedure and non-operation.Similar survival results were obtained in the analysis of patients with single tumor larger than 5 cm and 2-3 tumors larger than 3 cm.Conclusions: Although surgery rate declined from 2004 to 2015 in all HCC patients, it might be used more widely in patients with localized and regional tumors. And the treatment of surgery in patients with single tumor larger than 5 cm or patients with 2-3 tumors larger than 3 cm was worth trying.

show abstract

Section: Discussionmentioning

confidence: 99%

The trends and efficacy of operation in the treatment of hepatocellular carcinoma

Wu¹,

Chen²

2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…This endeavor however has to be taken cautiously, and patients that offered resection outside class A should be managed at high volume centers and at minimum be discussed at a multispecialty tumor board. With more and more BCLC staging system patients being considered for hepatectomy, the BCLC system should be revised to reflect modern liver surgery safety standards, and BCLC stages B should not be considered as absolute contraindications to surgery [6][7][8][9][10].…”

Section: The Bclc Systemmentioning

confidence: 99%

“…Several studies have been conducted comparing laparoscopic liver resection (LLR) versus open liver resection (OLR) for hepatocellular carcinoma (HCC), however, the optimal therapeutic approach has not been established [10,[14][15][16][17][18][19][20].…”

Section: Operative Approach: Open Vs Laparoscopic Hepatectomymentioning

confidence: 99%

Laparoscopic Liver Resection for Hepatocellular Carcinoma

Vlami¹,

Arkadopoulos²,

Hatzaras³

2022

Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), remains one of the most common causes of cancer-related death globally. HCC typically arises in the setting of chronic liver disease and cirrhosis and as such, treatment must be balanced between the biology of the tumor, underlying liver function and performance status of the patient. Hepatic resection is the procedure of choice in patients with high-performance status who harbor a solitary mass (regardless of size). Before the first laparoscopic hepatectomy (LH) was described as early as 1991, open hepatectomy (OH) was the only choice for surgical treatment of liver tumors. LH indications were initially based solely on tumor location, size, and type and was only used for partial resection of the anterolateral segments. Since then, LH has been shown to share the benefits of other laparoscopic procedures, such as earlier recovery and discharge, and reduced postoperative pain; these are obtained with no differences in oncologic outcomes compared to open resection. Specific to liver resection, LH can limit the volume of intraoperative blood loss, shorten portal clamp time and decrease overall and liver-specific complications. This chapter will offer an overview of standard steps are in pursuing laparoscopic liver resection, be it for a minor segmentectomy or a lobectomy.

show abstract

Liver Resection for Hepatocellular Carcinoma and the Barcelona Clinic Liver Cancer Criteria: Is It Time to Push the Limits?

Cited by 2 publications

References 18 publications

The trends and efficacy of operation in the treatment of hepatocellular carcinoma

The trends and efficacy of operation in the treatment of hepatocellular carcinoma

Laparoscopic Liver Resection for Hepatocellular Carcinoma

Contact Info

Product

Resources

About